Economic Evaluation of Third-Line Treatment with Alemtuzumab for Chronic Lymphocytic Leukaemia
- 76 Downloads
The objective of this study was to compare the potential economic efficiency of third-line treatment of chronic lymphocytic leukaemia (CLL) with alemtuzumab versus fludarabine, cyclophosphamide and rituximab (FCR).
The target population for this study were patients with CLL who were able to tolerate third-line treatment with either FCR or alemtuzumab. The perspective used was that of the New Zealand Pharmaceutical Management Agency (PHARMAC)/District Health Board. Health outcomes considered were survival time from commencement of treatment and quality-adjusted life-years (QALYs) gained. Average costs and outcomes and incremental cost per patient treated, per survival month and per QALY gained, were calculated. All costs were presented in 2006 New Zealand dollars.
Base-case direct medical costs for alemtuzumab per treatment regimen per patient were $NZ15 303 lower than those for FCR. The average direct medical cost per survival month gained for alemtuzumab was $NZ3144 and for FCR was $NZ4101, and the average direct medical cost per QALY gained was $NZ46 016 and for FCR was $NZ60 012.
Third-line treatment of eligible patients with alemtuzumab was found to be $NZ15 303 less costly than FCR per patient.
KeywordsChronic Lymphocytic Leukaemia Fludarabine Alemtuzumab Direct Medical Cost Chronic Lymphocytic Leukaemia Patient
A research grant from Bayer Schering Pharma, a division of Bayer New Zealand Limited, made this study possible but had no influence on the structure or content of the study research. Both authors were involved in all stages of the research and publishing process. At the time of the study the authors had no conflicts of interest that were directly relevant to the content of this study. One of the authors is now assisting with a PHARMAC application but was not doing so at the time of the study or writing of the paper.
- 3.New Zealand Health Information Service. Cancer registrations and deaths 2002. New Zealand Ministry of Health, 2002Google Scholar
- 4.Data on file, latest registration figures for lymphocytic leukaemia. Wellington: New Zealand Health information Service, 2007Google Scholar
- 5.Everybody: health information for New Zealanders. Leukemia [online]. Available from URL: http://www.everybody.co.nz [Accessed 2007 Aug 13]
- 6.Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003: 153-75Google Scholar
- 7.Algorithm for patients with CLL requiring treatment. Auckland: Auckland District Health Board, 2007: 1Google Scholar
- 10.Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York and Toronto: Oxford University Press, 1997Google Scholar
- 11.Thompson S, van Nooten F, van Agthoven M, et al. Cost and cost-effectiveness of FluCam versus FCR in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). 11th Congress of the European Haematology Association; 16–18 June 2006, AmsterdamGoogle Scholar
- 12.Thompson S, van Nooten F, van Agthoven M, et al. Cost- effectiveness of alemtuzumab (MabCampath®) in patients with B-cell chronic lymphocytic leukemia (CLL) who have failed alkylating agents and fludarabine. 11th Congress of the European Haematology Association; 16–18 June 2006, AmsterdamGoogle Scholar
- 14.New Zealand pharmaceutical schedule. Wellington, New Zealand: PHARMAC (Pharmaceutical Management Agency), 2006 AugGoogle Scholar
- 15.Data on file, New Zealand Health Information Service. Inpatient national prices. Wellington: New Zealand Health Information Service, 2006Google Scholar
- 16.New Zealand Ministry of Health. Hospital throughput 2002/03 [online]. Available from URL: http://www.moh.govt.nz [Accessed 2007 Aug 13]
- 17.Southern Cross Medical Care Society. VIP Plan 4 Schedule of benefits [online]. Available from URL: http://www.southerncross.co.nz/ [Accessed 2007 Aug 13]
- 18.Data on file, prices of saline, giving set, syringes, IV venflon. Christchurch, New Zealand: Ebos, 2006Google Scholar
- 19.Laboratory test purchase list. Wellington, New Zealand: Central Regional Health Authority, 1997Google Scholar
- 20.Commerce Commission. Commerce Act 1986: Business Acquisition Section 66. Notice Seeking Clearance: New Zealand Diagnostic Group Ltd & Sonic Healthcare (New Zealand) Ltd [online]. Available from: http://www.comcom.govt.nz [Accessed 2007 Aug 13]
- 21.Fraser G, Smith CA, Imrie K, et al. Alemtuzumab in chronic lymphocytic leukemia: a clinical practice guideline. Cancer Care Ontario; 2006 June 14. Report no.: 6-16: Section 1Google Scholar
- 23.Reserve Bank of New Zealand. Exchange rates and foreign exchange turnover, selected exchange rates and foreign exchange turnover data for selected currencies, B1 Exchange rates: bilateral rates and TWI [online]. Available from URL: http://www.rbnz.govt.nz/statistics/exandint/bl/ [Accessed 2007 Aug 13]
- 27.Zikmund WG. Business research methods. Fort West: Harcourt Brace College Publishers, 2000Google Scholar
- 28.Devlin N, Hanson P, Kind P. The health state preferences and logical inconsistencies of New Zealanders: a tail of two tariffs. Heslington: University of York Centre for Health Economics, University of York. Working papers, 2000: 180Google Scholar
- 32.@Risk version 4.5. Risk analysis and simulation add-in for Microsoft Excel. Newfield (NY): Palisade Corporation, 2004Google Scholar